دورية أكاديمية
أعرض في EDS

Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration.

التفاصيل البيبلوغرافية
العنوان: Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration.
المؤلفون: Mazaraki K; Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland., Fassnacht-Riederle H; Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland., Blum R; Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland., Becker M; Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland University of Heidelberg, Heidelberg, Germany., Michels S; Department of Ophthalmology, City Hospital Triemli, Zurich, Switzerland University of Zurich, Zurich, Switzerland.
المصدر: The British journal of ophthalmology [Br J Ophthalmol] 2015 Oct; Vol. 99 (10), pp. 1341-4. Date of Electronic Publication: 2015 Apr 15.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 0421041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2079 (Electronic) Linking ISSN: 00071161 NLM ISO Abbreviation: Br J Ophthalmol Subsets: MEDLINE
أسماء مطبوعة: Publication: Jan. 1992- : London : BMJ Pub. Group
Original Publication: 1917-Dec. 1991: London : British Medical Association
مواضيع طبية MeSH: Choroid/*pathology , Macular Degeneration/*drug therapy , Receptors, Vascular Endothelial Growth Factor/*administration & dosage , Recombinant Fusion Proteins/*administration & dosage , Tomography, Optical Coherence/*methods, Aged ; Female ; Fluorescein Angiography ; Follow-Up Studies ; Fundus Oculi ; Humans ; Intravitreal Injections ; Macular Degeneration/pathology ; Male ; Retrospective Studies ; Visual Acuity
مستخلص: Aim: Evaluation of effects of intravitreal aflibercept therapy on choroidal thickness (CT) in neovascular age-related macular degeneration.
Methods: Retrospective cohort study evaluating the change in CT following a loading dose of three intravitreal aflibercept injections at 4 weeks interval. Pretreated and treatment-naive eyes as well as untreated fellow eyes were evaluated at five retinal locations (subfoveal, 300 and 2500 µm nasal and temporal to the fovea) using spectral domain optical coherence tomography prior to and 4 weeks after a loading dose of three intravitreal aflibercept injections.
Results: A total of 84 treated eyes (61 pretreated, 23 treatment naive) and 48 fellow eyes were enrolled into the study. Treatment-naive and pretreated eyes showed a significant reduction in CT at all retinal locations. The effect was more pronounced in treatment-naive eyes. In the pretreated group, the mean reduction in CT was greatest at 2500 µm temporal to the fovea at 10.7 µm compared with 22.4 at 300 µm nasal to the fovea in the treatment-naive group. Only the fellow eyes in the treatment-naive group showed a significant CT reduction 12 weeks after initiation of therapy to the partner eye.
Conclusions: Aflibercept induces a reduction in CT in treatment-naive and pretreated eyes with neovascular age-related macular degeneration. There is some evidence of a systemic effect of aflibercept reflected by CT reduction in untreated fellow eyes.
(Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
References: Lancet. 2013 Oct 12;382(9900):1258-67. (PMID: 23870813)
Br J Ophthalmol. 2015 Jun;99(6):848-52. (PMID: 25595177)
Invest Ophthalmol Vis Sci. 2014 Mar;55(3):1352-60. (PMID: 24519422)
Invest Ophthalmol Vis Sci. 2014 Dec;55(12):7874-80. (PMID: 25395483)
Br J Ophthalmol. 2014 Dec;98(12):1636-41. (PMID: 25001321)
Graefes Arch Clin Exp Ophthalmol. 2014 Nov;252(11):1705-9. (PMID: 24614949)
Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1593-8. (PMID: 25047874)
JAMA Ophthalmol. 2013 May;131(5):693-4. (PMID: 23494008)
Ophthalmology. 2012 Dec;119(12):2537-48. (PMID: 23084240)
Ophthalmology. 2012 Jul;119(7):1388-98. (PMID: 22555112)
Am J Ophthalmol. 2007 Jun;143(6):995-1002. (PMID: 17449002)
N Engl J Med. 2006 Oct 5;355(14):1419-31. (PMID: 17021318)
N Engl J Med. 2004 Dec 30;351(27):2805-16. (PMID: 15625332)
Eye (Lond). 2014 Sep;28(9):1148-9. (PMID: 24833182)
Br J Ophthalmol. 2014 Sep;98(9):1201-4. (PMID: 24723615)
Br J Ophthalmol. 2014 Jun;98(6):813-25. (PMID: 24457369)
فهرسة مساهمة: Keywords: Angiogenesis; Choroid; Degeneration; Macula; Treatment Medical
المشرفين على المادة: 0 (Recombinant Fusion Proteins)
15C2VL427D (aflibercept)
EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
تواريخ الأحداث: Date Created: 20150417 Date Completed: 20151217 Latest Revision: 20220318
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4621373
DOI: 10.1136/bjophthalmol-2015-306636
PMID: 25877895
قاعدة البيانات: MEDLINE
الوصف
تدمد:1468-2079
DOI:10.1136/bjophthalmol-2015-306636